Elective and emergency cardiac surgery on a patient with hemophilia B

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 13, Issue 1, 1999, Pages 92-97

  Donahue, Brian S ^a   Emerson, Clifton W ^a   Slaughter, Thomas F ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Cardiac surgery; Congenital coagulopathy; Emergency operation; Hemophilia B; Recombinant factor IX

Indexed keywords

BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 9;

AGED; BLOOD TRANSFUSION; CASE REPORT; CONFERENCE PAPER; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; ELECTIVE SURGERY; EMERGENCY SURGERY; HEART MUSCLE ISCHEMIA; HEMOPHILIA B; HUMAN; INTENSIVE CARE UNIT; MALE; PATIENT MONITORING; PRIORITY JOURNAL; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL OBSERVATION; CLINICAL STUDY; CORONARY ARTERY BYPASS GRAFT; DIAGNOSIS; EMERGENCY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; REOPERATION;

AGED; AGED, 80 AND OVER; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; EMERGENCIES; HEMOPHILIA B; HUMANS; MALE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; REOPERATION; SURGICAL PROCEDURES, ELECTIVE;

EID: 0033072005     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(99)90181-7     Document Type: Conference Paper

References (37)

1. Newman MF, Croughwell ND, Blumenthal JA, et al: Cardiopulmonary bypass and the central nervous system: Potential for cerebral protection. J Clin Anesth 8:53S-60S, 1996
2. Jain U: Perioperative use of propofol for cardiac surgery. J Clin Anesth 8:61S-66S, 1996
3. Newman MF, Murkin JM, Roach G, et al: Cerebral physiologic effects of burst suppression doses of propofol during nonpulsatile cardiopulmonary bypass. Anesth Analg 81:452-457, 1995
4. Stone JG, Young WL, Marans ZS, et al: Consequences of electroencephalographic-suppressive doses of propofol in conjunction with deep hypothermie circulatory arrest. Anesthesiology 85:497-501, 1996
5. Scharfman WB, Rauch AE, Ferraris V, Burkart PT: Treatment of a patient with factor IX deficiency (hemophilia B) with coronary bypass surgery. J Thorac Cardiovasc Surg 105:765-766, 1993
6. Palanzo DA, Sadr FS: Coronary artery bypass grafting in a patient with haemophilia B. Perfusion 10:265-270, 1995
7. Santagostino E, Mannucci PM, Gringeri A, et al: Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. Thromb Haemost 71:737-740, 1994
8. Dimitrova A, Tsarianski G, Aleksandrov V, et al: [Hemophilia B and aortocoronary bypass] (Bulgarian). Khirurgiia 48:76-79, 1995
9. Bukowski JG, DeBrux JL, Ganascia B, et al: [Coronary artery bypass with extracorporeal circulation in a patient with hemophilia B] (French). Ann Fr Anesth Reanim 15:304-306, 1996
10. Djulbegovic B, Marasa M, Pesto A, et al: Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Am J Hematol 51:168-170, 1996
11. McLoughlin TM, Greilich PE: Preexisting hemostatic defects and bleeding disorders, in Lake CL, Moore RA (eds): Blood: Hemostasis, Transfusion, and Alternatives in the Perioperative Period. New York, NY, Raven, 1995, pp 25-70
12. Kasper CK: Postoperative thromboses in hemophilia B. New Engl J Med 289:160, 1973
13. Conlin MG, Hoots WK: Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery. Am J Hematol 35:203-207, 1990
14. Fuerth JH, Mahrer P: Myocardial infarction after factor IX therapy. JAMA 245:1455-1458, 1981
15. Scharrer I: The need for highly purified products to treat hemophilia B. Acta Haematol 94:2-7, 1995 (suppl 1)
16. Shapiro AD, Ragni MV, Lusher JM, et al: Safety and efficacy of monoclonal antibody-purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haeraost 75:30-35, 1996
17. Limentani SA, Gowell KP, Deitcher SR: High-purity factor IX concentrates for treatment of hemophilia B: Relative purity and thrombogenic potential. Acta Haematol 94:12-17, 1995 (suppl 1)
18. Negrier C, Vial J, Vinciguerra C, et al: Combined factor IX and protein C deficiency in a child: Thrombogenic effects of two factor IX concentrates. Am J Hematol 48:120-124, 1995
19. Aledort L: Inhibitors in hemophilia patients: Current status and management. Am J Hematol 47:208-217, 1994
20. Nicolaisen EM, Hansen LL, Poulsen F, et al: Immunological aspects of recombinant factor Vila (*rFVIIa) in clinical use. Thromb Haemost 76:200-204, 1996
21. Daily PO, Lamphere JA, Dembitsky WP, et al: Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: A randomized, prospective, double-blind study. J Thorac Cardiovasc Surg 108:99-108, 1994
22. Vander Salm TJ, Kaur S, Lancey RA, et al: Reduction of bleeding after heart operations through the prophylactic use of epsilonaminocaproic acid. J Thorac Cardiovasc Surg 112:1098-1107, 1995
23. Penta de Peppo A, Pierri MD, Scafuri A, et al: Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery: Prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J 22:231-236, 1995
24. Menichetti A, Tritapepe L, Ruvolo G, et al: Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: Aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg 37:401-407, 1996
25. Bennett-Guerrero E, Sorohan JG, Canada AT, et al: ∈-Aminoca-proic acid plasma levels during cardiopulmonaiy bypass. Anesth Analg 85:248-251, 1997
26. Djulbegovic B, Hannan MM, Bergman GE: Concomitant treatment with factor IX concentrates and antifibrinolytics in hemophilia B. Acta Haematol 94:43-47, 1995 (suppl 1)
27. Furie B, Furie BC: Molecular and cellular biology of blood coagulation. N Engl J Med 326:800-806, 1992
28. Roberts HR, Eberst ME: Other coagulation factor deficiencies, in Loscalzo J, Schafer AI (eds): Thrombosis and Hemorrhage. Boston, MA, Blackwell Scientific, 1994, pp 701-728
29. White GC II, Beebe A, Nielsen B: Recombinant factor IX. Thromb Haemost 78:261-265, 1997
30. Warren BB, Durieux ME: Hydroxyethyl starch: Safe or not? Anesth Analg 84:206-212, 1997
31. Treib J, Haass A, Pindur G: Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 78:974-983, 1997
32. Smith CR: Aprotinin versus lysine analogues: The debate continues. Ann Thorac Surg 65:S2-S8, 1998
33. Fremes SE, Wong BI, Lee E, et al: Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 58:1580-1588, 1994
34. Yost CS: Clinical utility and cost-effectiveness of aprotinin to reduce operative bleeding. Am J Anesthesiol 23:233-241, 1996
35. Dobkowski WB, Murkin JM: A risk-benefit assessment of aprotinin in cardiac surgical procedures. Drug Saf 1:21-41, 1998
36. Levy JH, Pifarre R, Schaff HV, et al: A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 92:2236-2244, 1995
37. Smith PK, Muhlbaler LH: Aprotinin: Safe and effective only with the full-dose regimen. Ann Thorac Surg 62:1575-1577, 1996